TRP Health Policy’s mission is to help people be healthy, and we understand that is the essence of your mission too. To get there in this rapidly evolving policy space, you need both political heft and substantive depth. That’s why we deliver insightful, actionable analysis and sophisticated, informed advocacy to help you achieve your goals.
The result: a government affairs partner that actually understands this stuff, empowering clients to get their answers first, understand them better, and act on them with unparalleled confidence and precision.
This is where we put the *know* in TRP Health Policy, and in you. Nowhere else will you find every reg, every hearing, every grant, every ACA section, every topic, every policy development broken down for you, with careful analysis and insight you can act on - now.
Our promise: you will understand every policy impacting your specific goals and be fully prepared to respond. We don’t sit back waiting for your call – keeping you one step ahead is our job. Our personalized, concierge service will give you the strongest platform for building your policy success.
Don’t react to policy, redefine it. With seasoned veterans of CMS and Capitol Hill’s healthcare committees, let us hone and amplify your message, ensuring it resonates with policymakers. In healthcare, it’s the right care. In policy, it’s the right message – at the right time, delivered to the right people. That’s where we excel.
Mylan agreed to pay $465 million to settle False Claims Act allegations it had misclassified EpiPen as a generic drug, resulting in the underpayment of Medicaid rebates. The DOJ says the settlement "resolves the government’s allegations that Mylan, by erroneously reporting EpiPen as a generic drug to Medicaid despite the absence of any therapeutically equivalent drugs, was able to demand... More (Zatorski, 8/17/17) #Generic Drugs, #Legal, #Pharmaceuticals
The Health Resources and Services Administration (HRSA) today proposed to further delay the effective date of a final rule titled “340B Drug Pricing Celling Price and Manufacturer Civil Monetary Penalties.” Today’s proposal would delay the effective date from Oct. 1, 2017 to July 1, 2018. This is fourth time the Administration has delayed the effective date of the rule, which... More (Horowitz, 8/17/17) #340B, #Pharmaceuticals